Iotamotion的FDA授权的机器人耳机植入系统已完成了1,000+程序,以更精确和安全的方式改善了听力治疗。 iotaMotion’s FDA-authorized robotic cochlear implant system has completed 1,000+ procedures, improving hearing treatment with greater precision and safety.

iotamotion, Inc.已使用FDA授权的iotaSOFT机器人辅助耳机植入系统完成了1 000多个临床程序,这是改善听力损失治疗的一个里程碑。 iotaMotion, Inc. has completed over 1,000 clinical procedures using its FDA-authorized iotaSOFT robotic-assisted cochlear implant system, a milestone in improving hearing loss treatment. 该系统是为12岁以上的病人设计的,提供精确、受控的电极插入,帮助保存内耳结构和减少外科风险。 Designed for patients 12 and older, the system offers precise, controlled electrode insertion, helping preserve inner ear structures and reduce surgical risks. 它在美国30多个中心使用,并在瑞士进行一项研究,目的是扩大全世界数百万人获得治疗的机会,尽管他们符合条件,但仍然得不到治疗。 Used in more than 30 U.S. centers and a study in Switzerland, it aims to expand access for the millions worldwide who remain untreated despite being eligible. 由于听力损失与大部分全球痴呆症病例有关,该技术解决了临床和心理障碍,提高了外科医生的信心和患者结果。 With hearing loss linked to a major portion of global dementia cases, the technology addresses both clinical and psychological barriers, enhancing surgeon confidence and patient outcomes.